PMID- 20875487
OWN - NLM
STAT- MEDLINE
DCOM- 20110215
LR  - 20191210
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 28
IP  - 50
DP  - 2010 Nov 23
TI  - The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine 
      (Tdap) less than 2 years following previous tetanus vaccination: Experience 
      during a mass vaccination campaign of healthcare personnel during a respiratory 
      illness outbreak.
PG  - 8001-7
LID - 10.1016/j.vaccine.2010.09.034 [doi]
AB  - BACKGROUND: Tdap is recommended for health care personnel (HCP) aged <65 years 
      who received tetanus diphtheria or tetanus toxoid immunization (Td/TT) >/=2 years 
      earlier. During a medical center Tdap vaccination campaign, we assessed the 
      safety of use of a Td/TT to Tdap interval <2 years in HCP. We also describe 
      reactogenicity in HCP who were aged >/=65 years or pregnant. METHODS: HCP 
      vaccinated with Tdap were surveyed to assess time since last Td/TT (>/=2 years vs. 
      <2 years), age, pregnancy status, and injection site adverse events (AEs) during 
      the 2 weeks after Tdap. AE rates were calculated and compared by non-inferiority 
      analysis using a predetermined margin of 10%. We searched clinic logbooks to 
      assess for clinically important adverse events during the 2 months after Tdap. 
      RESULTS: Of the 4524 vaccinated HCP, 2221 (49.1%) completed a safety survey which 
      met criteria for analysis. Non-inferiority analysis found that rates of moderate 
      and/or severe injection site AEs were not significantly greater in those 
      vaccinated <2 years than in those vaccinated >/=2 years after previous Td/TT. Three 
      serious adverse events were reported during the 2 months after vaccination, none 
      in persons who were >/=65 years, pregnant or received Td/TT <2 years before. 
      CONCLUSIONS: Our findings add to the body of evidence that a short interval 
      between Td/TT and a single dose of Tdap is safe.
CI  - Copyright (c) 2010 Elsevier Ltd. All rights reserved.
FAU - Talbot, Elizabeth A
AU  - Talbot EA
AD  - Dartmouth Medical School, Hanover, NH, USA. elizabeth.talbot@dartmouth.edu
FAU - Brown, Kristin H
AU  - Brown KH
FAU - Kirkland, Kathryn B
AU  - Kirkland KB
FAU - Baughman, Andrew L
AU  - Baughman AL
FAU - Halperin, Scott A
AU  - Halperin SA
FAU - Broder, Karen R
AU  - Broder KR
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20100925
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Diphtheria-Tetanus Vaccine)
RN  - 0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
RN  - 0 (Tetanus Toxoid)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Diphtheria-Tetanus Vaccine/administration & dosage
MH  - Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & dosage/*adverse 
      effects
MH  - Disease Outbreaks/*prevention & control
MH  - Female
MH  - Health Personnel/*statistics & numerical data
MH  - Health Surveys
MH  - Humans
MH  - *Immunization Schedule
MH  - Male
MH  - *Mass Vaccination
MH  - Middle Aged
MH  - Pregnancy
MH  - Tetanus Toxoid/administration & dosage
MH  - Time Factors
MH  - Whooping Cough/prevention & control
MH  - Young Adult
EDAT- 2010/09/30 06:00
MHDA- 2011/02/16 06:00
CRDT- 2010/09/30 06:00
PHST- 2010/04/12 00:00 [received]
PHST- 2010/08/24 00:00 [revised]
PHST- 2010/09/10 00:00 [accepted]
PHST- 2010/09/30 06:00 [entrez]
PHST- 2010/09/30 06:00 [pubmed]
PHST- 2011/02/16 06:00 [medline]
AID - S0264-410X(10)01344-7 [pii]
AID - 10.1016/j.vaccine.2010.09.034 [doi]
PST - ppublish
SO  - Vaccine. 2010 Nov 23;28(50):8001-7. doi: 10.1016/j.vaccine.2010.09.034. Epub 2010 
      Sep 25.